Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion
What happened
The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones
Summary assembled by rule from the sources below